Faculty

Bernardo H. Goulart, MD

Bernardo H. Goulart, MD

Acting Instructor
Seattle Cancer Care Alliance
Thoracic/Head and Neck
Department of Medicine , Division of Medical Oncology


Mailing Address

Seattle Cancer Care Alliance
825 Eastlake Ave E, G4-940
Seattle, WA 98109-1023

Admin Contact

Jeremy Puma
206.288.2048
hnlprogram@seattlecca.org
Fax: 206.288.2226

Specialty / Expertise

  • Head, Neck, and Lung

Research Interests

  • Head and neck and lung cancer outcomes research.
  • Economical evaluations of head and neck and lung cancer therapies.
  • Comparative effectiveness research in cancer.
  • Cost-effectiveness analyzes of cancer interventions.

Current Research Projects

N/A

Training

Dr. Goulart received his MD from Federal University of Rio de Janiero, Brazil and his Masters at University of Washington. He did his residency at the National Cancer institute of Brazil and than went on to complete his Internal Medicine Residency at the University of Washington in 2007 . He was a Post-Doctoral Fellow in Hematology/Oncology at Massachuesetts General/Harvard Medical School, Boston, MA.

Selected Publications

F.G.S. de Toledo, M.C. Albuquerque, B.H. Goulart, E.N. Chini. Different thermostabilities of sarcoplasmic reticulum (Ca2+ + Mg2+)- ATPases from rabbit and trout muscles. Comp. Biochem. Physiol. Vol. 111C, No.1, pp 93-98, 1995.

B. Goulart. Lactic Acidosis. Residência Médica. No 3, jan/march, 1999.

Goulart, B., Martins R.G., Lynch T.J. Twenty-two Years of Phase III Trials for Patients With Advanced Non-Small Cell Lung Cancer: Sobering Results. Letter. J Clin Oncol 2001; 15: 4089.

Roberts, TG; Goulart, BH; Squitieri, L; Stallings, SC; Halpern, EF; Chabner, BA; Gazelle, S; Finkelstein, S; Clark, JW. Trends in the risks and benefits to patients with cancer participating in phase I clinical trials. JAMA. 2004;292: 2130-2140.
[PubMed Abstract]

Roberts, TG; Goulart, BH; Clark, JW; Chabner, BA. Trends in the risks and benefits to patients with cancer participating in phase I clinical trials. Reply. JAMA. 2005;293: 795.

Goulart, BHL; Clark, JW; Pien, H; Roberts, TG; Finkelstein, S; Chabner, BA. Trends in the use and role of biomarkers in phase I oncology trials. Clin Cancer Res. 2007;13(22): 6719-6726.
[PubMed Abstract]

Goulart, BHL; Roberts, TG; Clark, JW; Chabner, BA. Trends in the use and role of biomarkers in phase I oncology trials. Reply to the Editor. Clin Cancer Res. 2008;14(8):2513.

Goulart, BH; Clark, JW; Lauwers GY; Ryan, DP; Grenon N., Muzikansky A; Zhu, AX. Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis. J Hematol Oncol. 2009, 2:13.
[PubMed Abstract]

Donelan K, Hobrecker K, Schapira L, Mailhot JR, Goulart BH, Chabner BA. Medical interpreter knowledge of cancer and cancer clinical trials. Cancer. 2009 Jul 15;115(14):3283-92.
[PubMed Abstract]

Fesinmeyer MD; Goulart B; Blough DK; Buchwald D; Ramsey SD. Lung cancer histology, stage, treatment, and survival in American Indians and Alaska Natives and Whites. Cancer. 2010. Oct 15;116(20):4810-6.

Carr LL; Mankoff DA; Goulart BH; Eaton, KD; Capell PT; Kell EM; Bauman JE; Martins RG. Phase II Study of Daily Sunitinib in FDG-PET Positive, Iodine Refractory, Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of Thyroid with Functional Imaging Correlation. Clinical Cancer Research. 2010. November;16(21):5260-8.
[PubMed Abstract]

Last updated: August 2011

Top